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Abstract Recently, a new paradigm for the development of
heart failure with preserved ejection fraction (HFpEF) has
been proposed, which identifies a systemic pro-
inflammatory state induced by comorbidities as the origin of
microvascular endothelial cell inflammation and subsequent
concentric cardiac remodeling and dysfunction. This review
further discusses the pivotal role of the inflamed endothelium
in the pathogenesis of HFpEF-specific cardiac remodeling.
The potential importance of reciprocal interactions of the
endothelium with cardiac fibroblasts and cardiomyocytes
and with the cardiac neurohumoral response in this cardiac
remodeling process is outlined.
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Introduction
Epidemiological studies demonstrate that 50 % of all heart
failure patients suffer from heart failure with preserved ejec-
tion fraction (HFpEF), which—in contrast to heart failure with
reduced ejection fraction (HFREF)—cannot be adequately
treated with current available therapeutical strategies [1].
Diabetes mellitus, obesity, hypertension, and COPD are the
main comorbidities associated with HFpEF. [2] The high
prevalence of HFpEF on the one hand and the rising preva-
lence of diabetes mellitus [3] and obesity [4] on the other
hand, indicate the need for HFpEF-specific therapies. Further
understanding of the underlying pathogenesis of HFpEF is
required in view of finding novel treatment options. Diastolic
stiffness underlying HFpEF is attributed to excessive
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myocardial collagen deposition and cardiomyocyte stiffness
[5], of which the latter newly has been shown to be sufficient
to induce HFpEF without any involvement of the extracellular
matrix [6•]. Recently, a novel paradigm was postulated which
identifies a systemic pro-inflammatory state induced by co-
morbidities as the origin of microvascular endothelial cell
inflammation, which triggers HFpEF-specific, i.e., concentric,
cardiac remodeling, and dysfunction [7••].
This review gives a brief overview on how systemic in-
flammation induced by comorbidities influences endothelial
cell behavior and signaling and how this affects the interaction
of the endothelium with cardiomyocytes and cardiac fibro-
blasts, and the cardiac neurohumoral response, and subse-
quent cardiac remodeling. On the other hand, this review
points out that those cells in turn influence the inflammation
or directly the endothelium, aggravating the initial inflamma-
tory process (Fig. 1). The impact of changes in substrate and
subsequent energy metabolism on the pathogenesis of HFpEF
is beyond the scope of this review.
Endothelial Dysfunction and Heart Failure with Preserved
Ejection Fraction
The endothelium, the physical barrier between the blood and
vascular wall, plays a pivotal role in cardiovascular homeo-
stasis by regulating vasomotor tone, vascular permeability,
and cardiac function [8]. The release of nitric oxide (NO) is
crucial for the normal function of the endothelium: NO medi-
ates vasodilatation, inhibits platelet aggregation, and protects
the integrity of the endothelial layer via its anti-inflammatory
Fig. 1 Impact of endothelial dysfunction on the pathogenesis of HFpEF.
Comorbodities such as obesity, hypertension, diabetes mellitus,
microalbuminuria, iron deficiency, and hypercoagulability induce a sys-
temic inflammatory state leading to increased VCAM-1 expression,
subsequent monocyte adhesion, and infiltration of inflammatory cells
releasing pro-inflammatory factors including interleukin (IL)-6, IL-8,
tumor necrosis factor (TNF)-α, and soluble ST2 (sST2), which promote
endothelial dysfunction. The resulting endothelial dysfunction is associ-
ated with impaired NO bioavailibilty and ROS production, leading to the
formation of peroxynitrite (ONOO−), all of which induce lowering of
protein kinase G (PKG) act ivi ty and subsequent ly t i t in
hypophosphorylation and an increased resting tension (Fpassive) of
cardiomyocytes. Intracellular calcium dysregulation involving dysfunc-
tion of the sarcoplasmic reticular adenosine triphosphate (ATP)-driven
pump (SERCA), phospholamban (PLB), and/or ryanodine receptors
(RYR) 2 further participates to cardiomyocyte stiffness. Low PKG activ-
ity and, among others, the release of endothelin-1 by activated endothelial
cells, contribute to cardiomyocyte hypertrophy. Furthermore, NO depri-
vation results in endothelial-to-mesenchymal transition (EndMT), a pro-
cess by which endothelial cells transdifferentiate into (myo)fibroblasts.
VCAM-1 and E-selectin expression on endothelial cells favors the adhe-
sion of leukocytes, which by releasing transforming growth factor β
(TGF-β) stimulate EndMT and the conversion of fibroblasts to
myofibroblasts and hereby cardiac fibrosis. By the release of, among
others, chemokines (monocyte chemotractant protein-1) and the induc-
tion of matrix metalloproteinases, (myo)fibroblasts stimulate the inflam-
matory process. Cardiac fibrosis, cardiomyocyte hypertrophy, and/or
cardiomyocyte stiffness contribute to wall stress and diastolic dysfunction
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[9–12], anti-apoptotic [13], and pro-angiogenic [14]
properties.
The HFpEF-associated comorbidities lead to endothelial
dysfunction, a condition characterized by impaired
endothelium-dependent vasodilatation and “endothelial acti-
vation,” referring to a state in which the endothelium loses its
physiological properties and shifts towards a pro-inflammato-
ry, pro-coagulatory, and vasoconstrictor state [15]. Particularly
hyperglycemia, activation of the renin-angiotensin system,
and tumor necrosis factor alpha (TNF-α) underlie decreased
NO bioavailability, the main characteristic of endothelial dys-
function, involving (1) deprivation of the substrate L-arginine
via impaired recycling of L-citrulline [16]; (2) increased
expression/activity of the natural competitor of endothelial
NO synthase (eNOS), arginase [17]; (3) reduced expression
of eNOS [12, 18]; (4) a decreased ratio of the eNOS dimer to
monomer [19]; (5) deprivation of the co-factor tetrabiopterin
[20]; and/or (6) eNOS uncoupling, a phenomena by which
eNOS produces superoxide (O2•) rather than NO [19, 21].
Hyperglycemia- or dyslipidemia-induced nicotinamide ade-
nine dinucleotide phosphate (NAD(P)H) oxidase (NOX) [22]
leads to O2• production and subsequent formation of
peroxynitrite (ONOO–), which enhances eNOS uncoupling
via reducing the affinity of eNOS for tetrabiopterin and via
limiting the de novo synthesis of tetrabiopterin [23].
The cardiac endothelium comprises the endothelial cells
of the coronary microvasculature, of the endocardium, and
of the intramyocardial capillaries. Cardiomyocytes lie with-
in the coronary microvascular network maximum 3 μm
from endothelial cells. This specific anatomical arrange-
ment allows not only adequate blood supply but also
facilitates the bidirectional communication among those
cells [24–26]. The relevance of the cardiac endothelium
in cardiac function follows from pioneer work from
Brutsaert et al. [27] who demonstrated in vitro that the
cardiac endocardial surface modulates the performance of
cardiac muscle. Via coronary infusion of substance P
leading to acute modulation of left ventricular (LV) func-
tion, Paulus et al. [28] provided later evidence that the
cardiac endothelium is important for cardiac contractile
function in humans potentially via the release of paracrine
factors including NO, endothelin-1, natriuretic peptides,
cytokines, and others. Both studies accentuate the signifi-
cance of the cardiac endothelium for (acute) cardiomyo-
cyte function. How the cardiac endothelium and conse-
quently endothelial dysfunction or deterioration affects
cardiomyocytes as well as cardiac fibroblasts and cardiac
neurohumoral activation will further be addressed in the
following paragraphs. The impact of the cardiac endothe-
lium on those different cardiac cells along with complex
(bidirectional) interactions accentuates the relevance of
endothelial dysfunction [29, 30] in the pathogenesis of
HFpEF.
Impact of Endothelial Dysfunction on Cardiac Fibroblasts
Cardiac Inflammation Triggers Cardiac Fibroblasts
Endothelial dysfunction/activation may contribute to car-
diac fibrosis by different means. Murdoch et al. [31]
recently demonstrated the role of endothelial NOX2 in
the induction of cardiac inflammation and fibrosis in
angiotensin II (Ang II) mice. Endothelium NOX2 trans-
genic mice had more vascular cell adhesion molecule
(VCAM)-1 positive blood vessels and inflammatory
cells after Ang II treatment than wild-type mice. In vitro
co-culture of endothelial cells overexpressing NOX2
with cardiac fibroblasts provided further evidence that
the induction of endothelial oxidative stress on its own
is not responsible for the induction of cardiac fibrosis
rather the stimulated inflammatory process. Since NO is
capable of reducing oxidative stress on the one hand
and dec r ea s i ng the exp r e s s i on o f monocy t e
chemoattractant protein-1 [9], VCAM-1 [10], and sub-
sequent adhesion of immune cells [11] on the other
hand, impaired NO bioavailability facilitates the engraft-
ment of immune cells. Subsequently, engrafted immune
cells may trigger cardiac fibrosis via inducing the dif-
ferentiation of fibroblasts into myofibroblasts, which is
reviewed in detail elsewhere [32••]. The importance of
inflammation in the induction of cardiac fibrosis and
heart failure, and particularly the role of the spleen as
monocyte reservoir, has recently been broadly demon-
strated [33–35]. In brief, we demonstrated that upon co-
culture with fibroblasts, splenocytes isolated from mice
with inflammatory cardiomyopathy induce a higher col-
lagen production in fibroblasts compared to splenocytes
from control mice [34]. Ismahil et al. [33] showed that
myocardial infarction is associated with cardiac inflam-
mation and concomitant depletion of splenic monocytes.
Furthermore, splenectomy experiments and adoptive
transfer of splenocytes from mice with heart failure in
naive recipients illustrated that splenocytes retain mem-
ory upon adoptive transfer and subsequently promote
immune-mediated fibrosis in the failing heart. Later,
van der Laan et al. [35] confirmed this unique spatio-
temporal pattern of monocyte accumulation in the myo-
cardium following myocardial infarction, which coin-
cides with a marked depletion of monocytes from the
spleen, in humans via analysis of human post-mortem
specimens of myocardium, spleen, and bone marrow.
Similar to splenocytes from myocarditis mice [34], we
demonstrated that co-culture of splenocytes from Ang
II-induced HFpEF mice induced a 46 % higher collagen
content in fibroblasts compared to splenocytes from
control mice. This suggests that also in the pathogenesis
of HFpEF, the cardiosplenic axis may be relevant. With
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respect to HFpEF, Westermann et al. [36] provided clear
evidence linking cardiac inflammation with TGF-β1-
induced collagen synthesis and diastolic dysfunction in
human subjects [37]. The role of TGF-ß as a pro-
fibrotic factor and its importance in the induction of
diastolic function follows from previous experiments
whereby the use of an anti-TGF-ß-neutralizing antibody
prevented myocardial fibrosis and diastolic dysfunction
in pressure-overloaded rats [38].
Besides immune cells, also fibrocytes, circulating
monocyte-derived cells with tissue remodeling properties of
fibroblasts [39], which are induced in cardiovascular disorders
[39, 40], can adhere to the activated endothelium, engraft in
the heart, and contribute to cardiac fibrosis.
Impaired Nitric Oxide Bioavailability Triggers Cardiac
Fibroblasts
Secondly, endothelial dysfunction contributes to cardiac fibro-
sis via the reduced bioavailability of NO, known to exert
direct anti-fibrotic effects involving the cyclic guanosine
monophosphate (cGMP) pathway [41, 42]. Vettel et al. [42]
recently demonstrated that the cGMP/cyclic adenosine
monophosphate (cAMP)-hydrolyzing phosphodiesterase
(PDE) 2, which is upregulated in human failing hearts [43],
leads to a decrease in cAMP levels in cardiac fibroblasts and
accelerates the conversion of fibroblasts to myofibroblasts.
Exogenous activation of cGMP via atrial natriuretic peptide
(ANP) or NO was able to bypass the PDE2-mediated degra-
dation of cAMP and reversed the differentiation of fibroblasts
into myofibroblasts. These data emphasize the benefit of
cGMP-elevating agents in the treatment of HFpEF which,
besides their well-recognized merit for cardiomyocytes, can
also be beneficial for cardiac fibroblasts. PDE5A inhibition
with sildenafil counteracted cardiac hypertrophy and adverse
remodeling in Ang II mice, an effect which was also associ-
ated with less cardiac inflammation [44]. These anti-
inflammatory effects of sildenafil, corroborated by Rizzo
et al. [45], consequently indirectly further support the role of
cardiac inflammation in cardiac remodeling and LV perfor-
mance. Furthermore, these findings confirm that besides
cardiomyocytes, also fibroblasts [46] and endothelial cells
[45] are target cells of sildenafil. Despite abovementioned
promising experimental findings [44], sildenafil failed to raise
cGMP levels and to ameliorate LV diastolic function in
HFpEF patients [47].
Endothelial-to-Mesenchymal Transition
Thirdly, NO deprivation [20, 48] leads to endothelial-to-
mesenchymal transition (EndMT), a process whereby endo-
thelial cells convert to a mesenchymal cell type, which can
give rise to fibroblasts. EndMT is induced by inflammatory
factors (TGF-ß [49] and TNF-α [50]), oxidized LDL [51], and
age [50]. In contrast, we could demonstrate that HDL decrease
EndMT. Zeisberg et al. (2007) [49] provided first evidence
that EndMT contributes to cardiac fibrosis during chronic
pressure overload. Recently, endothelial-specific expression
of endothelin-1 [52] and of NOX 2 [31] has been shown to
induce EndMT in experimental models of diabetes mellitus
and Ang II-induced cardiac hypertrophy and fibrosis, respec-
tively. Intriguingly, Ang II-induced endothelial NOX2 activa-
tion was associated with isolated diastolic dysfunction in the
absence of systolic dysfunction.
In summary, these findings suggest that endothelial
dysfunction/activation and downstream pathways including
not only inflammation but also far less appreciated EndMT,
are important mechanisms contributing to cardiac fibrosis and
the development of HFpEF [31]. Cardiac fibroblasts in turn
can further trigger cardiac inflammation [53] in a multimodal
manner which is reviewed in detail elsewhere [32••]. This
complex interaction among endothelial cells, inflammatory
cells, and cardiac fibroblasts might explain why unidirected
strategies [54] counteracting inflammation or fibrosis have
failed so far to block the fibrotic process and indicates the
need for new strategies with more broaden immunomodula-
tory effects [32••]. Furthermore, it stresses the need of diag-
nosing and treating HFpEF at an early stage of its pathogen-
esis, where the vicious circle of inflammation and fibrosis,
leading to chronic inflammation, might still be abrogated.
Impact of Endothelial Dysfunction on Cardiomyocytes
The endocardial endothelial cells and the endothelial cells of
intramyocardial capillaries regulate the contractile state of
cardiomyocytes via autocrine and paracrine signaling involv-
ing NO and endothelin-1. Furthermore, co-culture of cardiac
endothelial cells with cardiomyocytes protects those
cardiomyocytes from hydrogen peroxide-induced apoptosis
through neuregulin-erbB4 signaling [55]. This indicates that
cardiac endothelial cells exert direct anti-apoptotic effects in
addition to their role in oxygen supply, which is needed for
cardiomyocyte survival. Cardiac endothelial cells also guide
cardiomyocyte organization and promote physiological cou-
pling of cardiomyocytes and their synchronized contraction
via influencing the expression of the principal gap junction
protein connexin 43 [56]. On the other hand, upon inflamma-
tion [57] and mechanical load [58, 59], endothelial cells may
contribute to cardiomyocyte hypertrophy via the release of
endothelin-1. Cardiomyocytes in turn can affect the coronary
vasculature via multiple paracrine signals including
endothelin-1 and fibroblast growth factor 2 [60, 61]. In addi-
tion, cardiomyocytes affect long-term growth and develop-
ment of coronary arterial, venous, and lymphatic trees in
which the paracrine release of VEGF-A by cardiomyocytes
is of particular importance [60, 62]. This cardiomyocyte-
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vascular crosstalk plays a critical role in the vascular adapta-
tion, which takes place during myocardial hypertrophy. An
imbalance between vasculature and cardiomyocyte
growth may lead to progressive cardiac dysfunction
and heart failure [60]. In brief, the above findings
indicate the delicate balance between endothelial cells
and cardiomyocytes and imply that changes due to
endothelial dysfunction or deterioration may contribute
to cardiomyocyte hypertrophy and HFpEF.
Particularly, the contribution of cardiomyocyte stiffness in
diastolic LV stiffness and HFpEF is established. Besides in-
tracellular calcium dysregulation, involving dysfunction of
the sarcoplasmic reticular adenosine triphosphate (ATP)-driv-
en pump (SERCA), phospholamban (PLB), and/or ryanodine
receptor (RYR) 2, cardiomyocyte stiffness is mainly regulated
by the giant sarcomeric protein titin [63]. Titin spans the
sarcomere from the Z disk to the M line and functions as a
molecular spring supporting early diastolic recoil and late
diastolic distensibility of cardiomyocytes [64]. Evidence that
solely titin stiffness is sufficient to induce diastolic dysfunc-
tion and HFpEF, independent of extensive collagen deposi-
tion, follows from recent experimental studies. Chung et al.
generated mice with a deletion of nine immunoglobulin-like
domains from the proximal tandem immunoglobulin segment
of the titin spring region, which resulted in overall titin stiff-
ness [6•]. These knockout mice developed HFpEF despite
unaltered myocardial collagen content. In addition, Hamdani
et al. [65] recently demonstrated the importance of titin stiff-
ness in the induction of diastolic dysfunction independently of
cardiac fibrosis in a rat model of the metabolic syndrome.
Besides shortage of titin length by experimental deletion of
immunoglobulin-like domains [6•] or by oxidative stress-
induced formation of disulfide bridges within the titin mole-
cule [66], titin stiffness is also attributed to isoform shifts or
posttranscriptional modifications like phosphorylation or ox-
idation [64]. Protein kinase Cα phosphorylates titin at its
proline, glutamate, valine, and lysine (PEVK) titin region
and raises the stiffness of cardiomyoctes from normal myo-
cardium [67], but not from cardiomyocytes isolated from an
animal model of HFpEF [68]. On the other hand, the protein
kinase extracellular signal-regulated kinase 2 [69] and Ca2+/
calmodulin-dependent protein kinase II [70] phosphorylate
titin and lower cardiomyocyte stiffness, though their patho-
physiological relevance for HFpEF needs to be further clari-
fied. In HFpEF patients, titin at the stiff N2B isoform is
hypophosphorylated [71]. Protein kinases A [72] and G [73,
74••] phosphorylate titin at its N2B segment, and lower car-
diomyocyte stiffness, which implies that ß adrenergic stimu-
lation, NO, and natriuretic peptides may decrease cardiomyo-
cyte stiffness. With respect to Ca2+/calmodulin-dependent
protein kinase II and its involvement in NO synthesis as a
result of Ca2+-dependent activation of eNOS [75], it is tempt-
ing to speculate that Ca2+/calmodulin-dependent protein
kinase II may further contribute to the relaxation of titin via
triggering NO release. Due to the potential risk of arrhythmic
death, the induction of protein kinase A via ß adrenergic
stimulation is excluded as therapeutical option. Blocking the
breakdown of the downstream NO target cGMP via sildenafil
has not been successful in HFpEF patients despite promising
experimental studies (see infra). In contrast, favorable effects
in improving diastolic dysfunction in patients with HFpEF
have recently been found by the use of the neprilysin inhibitor
(LCZ696), which inhibits the breakdown of natriuretic pep-
tides. Neprilysin activity is induced in obese patients [76]. The
finding that IL-1ß induces neprilysin activity [77] may explain
the increased neprilysin and B-type natriuretic peptide (BNP)
paradox in obese HFpEF patients, which is associated with
increased inflammation [78].
In summary, the importance of NO bioavailability and
oxidative stress in titin relaxation (of the N2B segment)
[74••] as well as the role of inflammation in the induction of
neprilysin activity [77] and subsequent impaired natriuretic
signaling further corroborates the impact of endothelial dys-
function on cardiomyocyte stiffness.
Impact of Endothelial Dysfunction on Cardiac Neurohumoral
Regulation
As it has already been broadly outlined before, HFpEF co-
morbidities provoke a systemic inflammatory state, which
severely affects the coronary microvascular endothelium [36,
79]. The sum outcome of microvascular deterioration is neu-
ronal dysfunction and death as well as the reduction of
neurovascular perfusion, functional impairment, and cellular
apoptosis [80]. Inflammatory and hyperglycemia-induced ox-
idative stress in vascular endothelial cells correlates with
cardiac autonomic nerve dysfunction [81]. eNOS uncoupling
leading to nitrosative stress and formation of peroxynitrite
induces damage of neuronal axons, which are particularly
prone to oxidative and nitrosative stress due to their high
mitochondrial content [82]. This leads to a prominent abnor-
mality in the levels of cardioactive neuropeptides including
neuropeptide Y, substance P [83], calcitonin-generated pep-
tide, natriuretic peptides (ANP, BNP, and C-type natriuretic
peptide) [84] as well as the respective neuropeptide effectors
[85], contributing to impaired endothelium-dependent vaso-
dilation in HFpEF [86]. This limits the delivery and extraction
of tissue oxygen, which subsequently results in nerve hypoxia
and impaired nerve function [80]. The damage of the nerve
fibers innervating the heart and blood vessels, common for
cardiovascular autonomic neuropathy, results in abnormalities
in heart rate control and vascular dynamics. Besides their role
as vasodilatory proteins, the natriuretic peptides ANP and
BNP exert anti-fibrotic [87] and anti-hypertrophic effects
[88] and influence titin stiffness. Under metabolic conditions,
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BNP degradation seems to be paradoxically increased [89],
contributing to cardiac fibrosis and cardiomyocyte stiffness.
Cardiovascular autonomic neuropathy in diabetes mellitus
is associated with LV diastolic and systolic dysfunction, LV
hypertrophy, and higher LV mass index [90]. Findings from
studies of the autonomic nervous system indicate that it can
modulate inflammatory reactions [91]. These findings suggest
that dysregulation of the cardiac neurohumoral system not
only directly modulates vascular dynamics and heart function
but also activates cardiac inflammation and subsequent
remodeling.
Conclusions and Perspectives
HFpEF is a complex disorder caused by multifactorial
stresses secondary to comorbidities. This review highlights
the importance of endothelial dysfunction or deterioration
at the early onset of the pathogenesis of HFpEF and
stresses the subsequent complexity of cardiac remodeling
due to bidirectional interactions between endothelial cells,
cardiomyocytes, fibroblasts, and cardiac neurohumoral ac-
tivation. It further strengthens the need for an early diag-
nosis of endothelial dysfunction [92••] enabling treatment
before the development of HFpEF-specific cardiac remod-
eling. So far, only the prevention of HFpEF through
treatment of risk factors has been shown to be effective
[93]. It will be the challenge of finding new multidirec-
tional strategies to abrogate endothelial dysfunction and
subsequent cardiac remodeling. Given the importance of
inflammation in the induction of endothelial dysfunction
and cardiac remodeling via the cardiosplenic axis [33, 34],
intravenous application of mesenchymal stromal cells, and
the recently identified cardiac-derived adherent proliferat-
ing cells (CardAPs) [94] having immunomodulatory [34,
95–97], endothelium-protective [98], and anti-fibrotic [34,
99, 100] features might be attractive tools to counteract
the inflammatory and cardiac remodeling process.
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